Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
oncgnostics GmbH logo — Precision in Cancer Diagnostics

oncgnostics GmbH

Precision in Cancer Diagnostics

Founded 2012 Germany Jena, Germany 25 employees Total: $1.00M Biotechnology, Health Care +1

General Information

Company Name oncgnostics GmbH
Founded Year 2012
Location Germany Jena, Germany
Employees 25
Industries Biotechnology, Health Care, Robotics
Business Model B2B2C, B2B, White Label
Revenue Model Product Sales, Licensing, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with oncgnostics GmbH. To contact oncgnostics GmbH, visit oncgnostics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About oncgnostics GmbH

Oncgnostics GmbH, founded in 2012 and headquartered in Germany, is gaining traction in the biotechnology sector under its slogan, "Precision in Cancer Diagnostics." The company specializes in developing molecular in vitro diagnostic (IVD) tests utilizing proprietary epigenetic biomarkers. This innovative approach aims to enhance the precision of screening, follow-up care, and therapeutic decision-making in cancer diagnostics.

Operating at the intersection of Biotechnology, Health Care, and Robotics, oncgnostics GmbH stands out for its focus on reliability and precision—key factors in medical diagnostics. The company's recent early VC investment closed on 01 September 2023, led by Grand Ventures, signals investor confidence in its promising diagnostic solutions.

Overall, oncgnostics GmbH is well-positioned to capitalize on growing demands for accurate cancer diagnostics, offering a compelling opportunity for investors seeking innovation in health technology.

Taxonomy: Cancer Diagnostics, Epigenetic Biomarkers, In Vitro Diagnostic Tests, PCR-based Technologies, Molecular Diagnostics, Cervical Cancer Detection, DNA Methylation, Assay Development, Routine Molecular Diagnostics, Screening Tests, Therapeutic Decision-Making, Follow-up Care, Precancerous Lesions Detection

Services & Products

Entwicklung von molekulardiagnostischen Tests
Früherkennung und Diagnose von Krebs mittels Biomarkern
Klinische Validierung von diagnostischen Tests

Target Customers

Diagnostiklabore Pharmaunternehmen Krankenhäuser Ärzte und Onkologen

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC Undisclosed 1
Grand Ventures
Grand Ventures
01 Sep 2023
Support Program €2.50K 1
EIT Health
01 Oct 2019
Grant Undisclosed -
01 Jan 2018
Early VC €1.00M 1
bm-t Beteiligungsmanagement Thüringen
01 Feb 2017
Series A Undisclosed 5
HTGF Sparkasse Jena-Saale-Holzland Fil. Großer Brühl
HTGF, Sparkasse Jena-Saale-Holzland Fil. Großer Brühl +3
01 Jan 2015
Spinout Undisclosed 2
HTGF
HTGF, STIFT Thueringen
01 Apr 2012

oncgnostics GmbH Alternatives & Competitors

View All Alternatives
oncgnostics GmbH vs
PreCyte Inc
PreCyte Inc United States

Envisioning a world free from cancer and neurodegenerative disease

3 employees
Biotechnology, Health Care
oncgnostics GmbH vs
Nucleix Ltd.
Nucleix Ltd. Israel

Developing cancer diagnostic panels based on epigenetic bio markers

72 employees
Biotechnology, Health Care
Compare oncgnostics GmbH vs Nucleix Ltd.
oncgnostics GmbH vs
Amadix
Amadix Spain

Early cancer detection in blood

Grant
43 employees
Biopharma, Biotechnology
Compare oncgnostics GmbH vs Amadix
Also compare with: oncgnostics GmbH vs LungLife AI LungLife AI View all alternatives

FAQ About oncgnostics GmbH

Precision in Cancer Diagnostics
oncgnostics GmbH was founded in 2012.
oncgnostics GmbH is headquartered in Jena, Germany.
oncgnostics GmbH operates in Biotechnology, Health Care and Robotics. Its work centres on Cancer Diagnostics, Epigenetic Biomarkers, In Vitro Diagnostic Tests and PCR-based Technologies. Its customers include Diagnostiklabore, Pharmaunternehmen and Krankenhäuser.
oncgnostics GmbH has a B2B2C, B2B and White Label business model. Its revenue comes from Product Sales, Licensing and Usage Based.
oncgnostics GmbH has approximately 25 employees.
oncgnostics GmbH has completed 6 funding rounds, raising a total of $1.00M.
oncgnostics GmbH offers: Entwicklung von molekulardiagnostischen Tests, Früherkennung und Diagnose von Krebs mittels Biomarkern, Klinische Validierung von diagnostischen Tests.
Top alternatives and competitors to oncgnostics GmbH include PreCyte Inc, Nucleix Ltd., Amadix, Beacon Biomedical, Singlera Genomics Incorporated. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
oncgnostics GmbH and PreCyte Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for oncgnostics GmbH, https://bouncewatch.com/company/oncgnostics-gmbh, updated 14 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes